drugset
drugset / Trial / NCT01925950

Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)

NCT01925950 ↗

Phase 2 Terminated 2 enrolled Soligenix
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Use of an oral topically-active glucocorticoid with limited side effects may control the gastrointestinal inflammatory process of GVHD and minimize glucocorticoid exposure.

Timeline

Start
2013-12
Primary completion
2015-05
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject beclomethasone dipropionate Other / unclassified — Oral

Indications

chronic graft versus host disease